Plaque psoriasis and psoriatic arthritis associated with uveitis and cystoid macular edema treated with adalimumab: A case report and literature review

After careful consideration of the patient's underlying and comorbid conditions and previous treatment failures, adalimumab was instituted and continued since (1) its efficacy in psoriasis and psoriatic arthritis is well-documented; (2) obesity is not thought to affect its effectiveness; (3) in uveitis adalimumab acts quickly and induces long-term remission; (4) a significant improvement of hemostasis and fibrynolytic balance has been observed in patients on TNF-α inhibitors and adalimumab could be continued after the TIA.